国际肿瘤低价值医疗服务研究进展OA

Objective This study aims to explore the research frontiers and hotspots in the field of low-value care in oncology through bibliometrics and visualization analysis,and to provide a reference for future theoretical research and practice in this field.Methods English-language literature on low-value care in oncology from 2000 to 2025 was systematically retrieved from the PubMed database.CiteSpace was employed to conduct co-occurrence analysis,cluster analysis,timeline visualization,and burst detection.Subgroup analyses were performed for four major solid tumors:breast cancer,prostate cancer,thyroid cancer,and lung cancer.Results A total of 2 367 publications were included.Since 2012,the publication volume has surged,with the United States contributing a significantly higher volume than other countries.Co-occurrence analysis identified high-frequency keywords such as breast cancer,prostate cancer,drug interactions,thyroid cancer,geriatric assessment,lung cancer,and active surveillance.Cluster analysis identified ten major clusters,including polypharmacy,prostate cancer,breast cancer,and cancer screening.The timeline view demonstrated a shift from studies focused on individual low-value practices to those addressing comprehensive value-based governance.Burst detection highlighted potentially inappropriate medication(PIM)and drug interactions as current research frontiers.Keyword co-occurrence analyses of the four high-frequency cancer subgroups indicated that cancer screening and imaging examinations are the focal points of low-value care,while also revealing heterogeneity in practices across different tumor types.Conclusions Research on low-value care in oncology evolves rapidly,currently focusing on screening services for high-incidence solid tumors(e.g.,breast and prostate cancer)and medication management for the seniors.Future research should expand value assessment across a broader range of cancer types,strengthen the translation of evidence into practice,promote the development of new technologies,and formulate value-based healthcare management strategies to advance precision and high-value oncology practices.